Skip to content ↓

Topic

Economics

Download RSS feed: News Articles / In the Media / Audio

Displaying 526 - 540 of 978 news clips related to this topic.
Show:

Reuters

Prof. Joshua Angrist, Prof. David Card of the University of California at Berkeley and Prof. Guido Imbens of Stanford have been awarded the 2021 Nobel Prize in Economics for “pioneering ‘natural experiments’ to show real-world economic impacts,” reports Simon Johnson and Niklas Pollard for Reuters. “The Nobel committee noted that natural experiments were difficult to interpret, but that Angrist and Imbens had, in the mid-1990s, solved methodological problems to show that precise conclusions about cause and effect could be drawn from them,” write Johnson and Pollard.

New York Times

New York Times reporter Jeanna Smialek explores the work of Prof. Joshua Angrist, who was honored as a recipient of the 2021 Nobel Prize in Economics for his work developing “research tools that help economists use real-life situations to test big theories, like how additional education affects earnings.” Angrist and his fellow recipients David Card and Guido Imbens “ushered in a new phase in labor economics that has now reached all fields of the profession,” said Prof. Trevon D. Logan of Ohio State.

The Boston Globe

Prof. Joshua Angrist was named a winner of the 2021 Nobel Prize for Economics for “a body of work stretching across decades that has sought to answer the complex questions at the crux of modern political discussion through the lens of proven research,” writes Andrew Brinker for The Boston Globe. “It’s just the greatest honor a person could have,” said Angrist. “It’s a high point of my life.”

WBUR

Prof. David Autor joins On Point to discuss the economic and social crisis facing American men. “It matters because we care about the welfare of all individuals,” says Autor. “It affects the people they would partner with, their potential spouses. It affects their children. It affects the level of crime incarceration. It affects the tax base. it affects our ability to grow and innovate in all kinds of ways. We're all kind of in this together.”

Fast Company

Speaking at the Fast Company Innovation Festival, Profs. Esther Duflo and Abhijit Banerjee underscored the need for “governments need to do better in addressing different needs within their populations, and providing variations of cash relief for different circumstances.”

Fortune

Fortune reporter Shawn Tully writes that a new study co-authored by MIT researchers that examines the amount of e-waste Bitcoin generates. The researchers found that: “In 2020, the Bitcoin network processed 120 million transactions,” writes Tully. “For every sale or purchase recorded on the blockchain, the miners disposed of e-waste equal in weight to two iPhone 12 Minis. In other words, the industry trashed the equivalent of 240 million of the 135 gram mobile devices.”

VICE

Research affiliate Hunt Allcott speaks with Vice reporter David Shultz about his research on the nutrition gap in America. Allcott and his colleagues “have proposed a sort of expansion on the soda tax, in which unhealthy foods are taxed more, and that money is used to subsidize healthier foods,” writes Shultz.

New York Times

New York Times columnist Thomas B. Edsall spotlights Prof. David Autor’s research exploring the state of men in the U.S., including the growing gender gaps in educational attainment and the labor market.   

Reuters

A new study co-authored by Institute Professor Daron Acemoglu finds that countries with older workforces are seeing a larger increase in the use of robots, reports Timothy Aeppel for Reuters. Acemoglu and his colleague Pascual Restrepo of Boston University found that “age alone accounted for 35% of the variation between countries in their adoption of robots, with those having older workers far more likely to adopt the machines.”

New York Times

Writing for The New York Times, Prof. David Autor explores how the current labor shortage provides an opportunity to improve the quality of jobs in the U.S. “The period of labor scarcity, then, is an opportunity to catalyze better working conditions for those who need them most,” writes Autor.

GBH

Prof. David Autor speaks with Kara Miller of GBH’s Innovation Hub about the impact of Covid-19 on the future of work.

GBH

Prof. Jonathan Gruber speaks with Margery Eagan and Jared Bowen on Boston Public Radio about the ethics of offering vaccine booster shots in the U.S. when many nations are struggling with vaccine scarcity. “This is really a moment where, going forward, the world has to figure out a more effective strategy,” said Gruber. “We need to think about how we’re going to set up institutions to deal with these kinds of tradeoffs in the future.” 

New York Times

New York Times columnist Peter Coy spotlights a new working paper by Prof. Daron Acemoglu examining democracies. “Democracies breed their own support only when they are successful: all of the effects we estimate work through exposure to democracies that are successful in providing economic growth, peace and political stability, and public goods,” Acemoglu and his co-authors write.

Project Syndicate

Institute Prof. Daron Acemoglu writes for Project Syndicate about why the U.S. and its allies never reconsidered a top-down state-building strategy in Afghanistan. “In viewing nation-building as a top-down, ‘state-first’ process, US policymakers were following a venerable tradition in political science,” writes Acemoglu. “The assumption is that if you can establish overwhelming military dominance over a territory and subdue all other sources of power, you can then impose your will. Yet in most places, this theory is only half right, at best; and in Afghanistan, it was dead wrong.”

New York Times

Writing for The New York Times, Prof. Amy Finkelstein explores the need to reign in prices of drugs administered by physicians. “Economists tend to favor letting the private sector set prices, but this requires a well-functioning market,” writes Finkelstein. “In trying to base its payments on what other customers pay, Medicare has distorted the market for physician-administered drugs beyond reason.”